3-methyl-2,3,4,5-tetrahydro-1H-benz[d]azepine; hydrochloride | 34583-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 3-methyl-2,3,4,5-tetrahydro-1H-benz[d]azepine; hydrochloride
• 英文别名: 3-Methyl-2,3,4,5-tetrahydro-1H-benz[d]azepin; Hydrochlorid；3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride；3-methyl-1,2,4,5-tetrahydro-3-benzazepine;hydrochloride
• CAS: 34583-81-8
• 化学式: C₁₁H₁₅N*ClH
• 分子量: 197.708
• InChiKey: BFJICZNYWFEORW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.14
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-methyl-2,3,4,5-tetrahydro-1H-benz[d]azepine; hydrochloride 、 3-氯丙酰氯 在 三氯化铝 sodium 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 生成 1-(3-Methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)2-propen-1-one hydrochloride
  参考文献：
  名称：

  Condensed heterocyclic ketone derivatives and their use

  摘要：

  该化合物的分子式为：##STR1##其中R.sup.1为H或可选择取代的烃基或酰基；环A为可选择进一步取代的苯环；n为1到10的整数；R.sup.2、R.sup.3和R.sup.4为H或可选择取代的烃基；R.sup.3和R.sup.4可以与相邻的氮原子一起形成可选择取代的杂环基；k为0到3的整数；m为1到8的整数；但当k=0且m=2时，n为不少于2的整数或其药学上可接受的盐，表现出优异的胆碱酯酶抑制活性和单胺再摄取抑制活性，因此可用作治疗/预防老年性痴呆的药物。

  公开号：

  US05462934A1

文献信息

• Condensed heterocyclic ketone derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0560235B1

  公开（公告）日：1997-06-04
• ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2611449A1

  公开（公告）日：2013-07-10
• US5462934A
  申请人：——

  公开号：US5462934A

  公开（公告）日：1995-10-31
• [EN] ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT<br/>[FR] ADMINISTRATION DE LORCASÉRINE À DES INDIVIDUS PRÉSENTANT UNE INSUFFISANCE RÉNALE
  申请人：ARENA PHARM INC

  公开号：WO2012030939A1

  公开（公告）日：2012-03-08

  The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.
• [EN] PROCESSES FOR THE PREPARATION OF 5-HT2C RECEPTOR AGONISTS<br/>[FR] PROCÉDÉS POUR LA PRÉPARATION D'AGONISTES DU RÉCEPTEUR 5-HT2C
  申请人：ARENA PHARM INC

  公开号：WO2011153206A1

  公开（公告）日：2011-12-08

  Processes and intermediates for preparing salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and pharmaceutically acceptable solvates and hydrates thereof, that are useful for, inter alia, weight management.